GEN Exclusives

More »

GEN News Highlights

More »
Jun 12, 2013

Promising Phase III Results for Amgen Ovarian Cancer Candidate

  • Announcing top-line results from its Phase III TRINOVA-1 trial evaluating trebananib plus paclitaxel vs. placebo plus paclitaxel in recurrent ovarian cancer, Amgen today said its drug had met its primary endpoint of progression-free survival.

    The firm observed a 34% reduction in the risk of disease progression or death in patients given trebananib plus paclitaxel, compared with placebo.

    Overall, median progression-free survival was 7.2 months with trebananib arm vs. four months in the control arm, Amgen said, noting it expects to report overall survival results in 2014.

    "Angiopoietin inhibition has been a focus of research at Amgen and these results suggest that the novel biology of trebananib may offer a promising approach for patients with ovarian cancer,” Sean E. Harper, M.D., evp of R&D at Amgen said in a statement.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?